Circulatory Coherence in COVID-19 and Non-COVID-19 Patients With Sepsis

Circulatory and Endothelial Coherence in COVID-19 and Non-COVID-19 Patients With Sepsis - Prospective, Observational Pilot Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04644302

Enrollment

Registered

2020-11-25

Start date

2020-02-01

Completion date

2021-07-01

Last updated

2021-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis, Viral Pneumonia

Keywords

microcirculation, endothelial glycocalyx, COVID-19

Brief summary

This prospective observational pilot study investigates circulatory coherence in patients with COVID and non-COVID sepsis by comparison of microcirculation, endothelial glycocalyx, and clinical course

Detailed description

This prospective observational pilot study investigates circulatory coherence in patients with COVID and non-COVID sepsis by comparison of microcirculation (sublingual area video recordings and biochemical parameters of endothelial cells activation and damage) endothelial glycocalyx (sublingual area video recordings and biochemical parameter of glycocalyx degradation), and clinical course.

Interventions

DIAGNOSTIC_TESTmicrocirculation recording

non-invasive recording of sublingual microcirculation and blood sampling together with regular withdraws

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* adult * ICU admission due to sepsis with organ failure * need for organ support therapy (mechanical ventilation, CRRT, ECMO) * clinical and/or laboratory signs of circulatory instability

Exclusion criteria

* family withdrawal/disagreement * death within three days from ICU admission

Design outcomes

Primary

Measure	Time frame	Description
change in Proportion of Perfused Vessels (PPV) parameter	1st, 2nd and 3rd day	PPV describes microcirculation dysfunction
change in Syndecan-1 serum concentration	1st, 2nd and 3rd day	Syndecan-1 is a marker of endothelial glycocalyx

Secondary

Measure	Time frame	Description
change in albuminuria	1st, 2nd and 3rd day	albuminuria is a marker of glomerular endothelial cells dysfunction
mortality in 28 days	30 days	mortality in 28 days from ICU admission

Countries

Czechia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026